Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.
Executive Director at TW Consulting Group
For the last 5 years, Tom has partnered with pharma and biotech organizations to design their strategy for Pre-approval Access and develop global programs, allowing patients to gain access to treatments that would otherwise be unavailable to them whilst supporting traditional development pathways.
His role as Head of U.S. Business Development for IDIS Managed Access, part of the Clinigen Group, provided a platform to help patients around the world whilst developing thinking and strategy for many of the Top 20 Pharma companies in this important area.
In his current role, Tom is looking to make a broader and significant positive impact on the Pre-approval Access landscape finding solutions for many of the hurdles that exist for companies interested in satisfying the immediate needs of patients whilst balancing developmental objectives.
TW Consulting Group is the leading platform for Pharma and Biotech clients to access pre-approval access global experts. The Group devises successful pre-approval strategies for the benefit of all stakeholders.
Before working in this space, Tom spent 14 years within the pharmaceutical industry fulfilling a range of leadership roles including Head of Marketing for a multinational pharma company. Within this time, he led a wide range of global pre-launch and launch activities for treatments addressing areas of high unmet medical need.
Tom is a member of the New York University School of Medicine Working Group on Compassionate Use and Pre- Approval Access and a Strategic Advisor for WideTrial. He is deeply committed to helping companies with promising medicines in development and the patients they serve.